

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8122)

**PROPOSED TRANSFER OF LISTING
FROM THE GROWTH ENTERPRISE MARKET
TO THE MAIN BOARD OF
THE STOCK EXCHANGE OF HONG KONG LIMITED**

The board of directors (the “**Board**”) wishes to announce that LifeTech Scientific Corporation (the “**Company**”) made an application for the transfer (the “**Transfer**”) of the listing of the Company’s shares (the “**Shares**”) from the Growth Enterprise Market (“**GEM**”) to the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 31 May 2013 under Chapter 9A of the Rules Governing the Listing of Securities on the Stock Exchange.

The Company and its subsidiaries (collectively, the “**Group**”) is principally engaged in developing, manufacturing and marketing advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The directors of the Company (the “**Directors**”) believe that the Transfer will help to enhance the profile of the Group and also improve the trading liquidity of the Shares. The Board is of the view that the Transfer will be beneficial to future growth, financial flexibility and business development of the Company.

There is no assurance that permission will be obtained from the Stock Exchange for the Transfer. Shareholders and potential investors should be aware that the implementation of the Transfer is subject to, among other things, the granting of the relevant approval by the Stock Exchange and thus the Transfer may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

The Company will make further announcement to keep the shareholders and potential investors informed on the progress of the Transfer.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Chairman and Executive Director

Shenzhen, P.R.C., 31 May 2013

As at the date of announcement, the Board comprises Mr. XIE Yuehui and Mr. ZHAO Yiwei Michael being executive directors of the Company; Mr. WU Jianhui, Mr. MARTHA Geoffrey Straub and Dr. LIDDICOAT John Randall being non-executive directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHANG Xingdong and Mr. ZHOU Gengshen being independent non-executive directors of the Company.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and (ii) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for 7 days from the date of its posting. This announcement will also be posted on the Company’s website at <http://www.lifetechmed.com>.